ATE309223T1 - Cyclin-abhängige kinase inhibitoren - Google Patents
Cyclin-abhängige kinase inhibitorenInfo
- Publication number
- ATE309223T1 ATE309223T1 AT99913426T AT99913426T ATE309223T1 AT E309223 T1 ATE309223 T1 AT E309223T1 AT 99913426 T AT99913426 T AT 99913426T AT 99913426 T AT99913426 T AT 99913426T AT E309223 T1 ATE309223 T1 AT E309223T1
- Authority
- AT
- Austria
- Prior art keywords
- cyclin
- cdk
- kinase inhibitors
- dependent kinase
- inhibitors
- Prior art date
Links
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title abstract 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title 1
- 108091007914 CDKs Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9806739.0A GB9806739D0 (en) | 1998-03-28 | 1998-03-28 | Cyclin dependent kinase inhibitors |
| PCT/GB1999/000830 WO1999050251A2 (en) | 1998-03-28 | 1999-03-29 | Cyclin dependent kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE309223T1 true ATE309223T1 (de) | 2005-11-15 |
Family
ID=10829498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99913426T ATE309223T1 (de) | 1998-03-28 | 1999-03-29 | Cyclin-abhängige kinase inhibitoren |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1066266B1 (de) |
| JP (1) | JP2002509921A (de) |
| AT (1) | ATE309223T1 (de) |
| AU (1) | AU753716B2 (de) |
| CA (1) | CA2326357A1 (de) |
| DE (1) | DE69928235T2 (de) |
| ES (1) | ES2253881T3 (de) |
| GB (1) | GB9806739D0 (de) |
| WO (1) | WO1999050251A2 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5636900A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| GB0101686D0 (en) * | 2001-01-23 | 2001-03-07 | Cancer Res Campaign Tech | Cyclin dependent kinase inhibitors |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| AU2002312933B2 (en) | 2001-05-29 | 2007-12-06 | Schering Ag | CDK inhibiting pyrimidines, production thereof and their use as medicaments |
| GB0113041D0 (en) * | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| JP2005524672A (ja) | 2002-03-09 | 2005-08-18 | アストラゼネカ アクチボラグ | Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体 |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| BR0313059B8 (pt) | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| CN102358738A (zh) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
| TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| JP5095409B2 (ja) | 2004-11-24 | 2012-12-12 | ライジェル ファーマシューティカルズ， インコーポレイテッド | スピロ２，４−ピリミジンジアミン化合物およびその使用 |
| WO2007036732A1 (en) | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
| US20090069180A1 (en) * | 2006-02-15 | 2009-03-12 | Joachim Rheinheimer | 2-substituted pyrimidine derivatives |
| ES3066112T3 (en) | 2015-12-24 | 2026-05-11 | The Regents Of The Univ Of California | Cftr regulators and methods of use thereof |
| CN107118162A (zh) * | 2017-04-28 | 2017-09-01 | 大连联化化学有限公司 | 2，4，5‑三氨基‑6‑环已基氧基嘧啶盐酸盐的制备方法 |
| WO2019157020A1 (en) | 2018-02-06 | 2019-08-15 | The Board Of Trustees Of The University Of Illinois | Substituted benzothiophene analogs as selective estrogen receptor degraders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1092343B (it) * | 1978-02-02 | 1985-07-06 | Poli Ind Chimica Spa | Pirimidilsolfuri ad attivita' antisecretoria,processo per la loro preparazione e composizioni farmaceutiche che li contengono |
| JPH02308248A (ja) * | 1989-05-24 | 1990-12-21 | Fuji Photo Film Co Ltd | アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料 |
| PT612314E (pt) * | 1991-10-30 | 2000-06-30 | Astra Ab | Derivados de etilamina 2-heterociclicos e seu uso como produtos farmaceuticos |
| US5622977A (en) * | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
| KR100257129B1 (ko) * | 1993-09-11 | 2000-05-15 | 성재갑 | 신규 세팔로스포린계 항생제 및 이의 제조방법 |
| US5929046A (en) * | 1994-06-08 | 1999-07-27 | Cancer Research Campaign Technology Limited | Pyrimidine and purine derivatives and their use in treating tumour cells |
| US5525606A (en) * | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
| FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| JPH09301958A (ja) * | 1996-05-09 | 1997-11-25 | Nippon Shoji Kk | 新規ピリミジン化合物及び抗ロタウイルス剤 |
| US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
-
1998
- 1998-03-28 GB GBGB9806739.0A patent/GB9806739D0/en not_active Ceased
-
1999
- 1999-03-29 CA CA002326357A patent/CA2326357A1/en not_active Abandoned
- 1999-03-29 JP JP2000541156A patent/JP2002509921A/ja active Pending
- 1999-03-29 AU AU31551/99A patent/AU753716B2/en not_active Ceased
- 1999-03-29 WO PCT/GB1999/000830 patent/WO1999050251A2/en not_active Ceased
- 1999-03-29 AT AT99913426T patent/ATE309223T1/de not_active IP Right Cessation
- 1999-03-29 EP EP99913426A patent/EP1066266B1/de not_active Expired - Lifetime
- 1999-03-29 DE DE69928235T patent/DE69928235T2/de not_active Expired - Fee Related
- 1999-03-29 ES ES99913426T patent/ES2253881T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999050251A2 (en) | 1999-10-07 |
| JP2002509921A (ja) | 2002-04-02 |
| AU753716B2 (en) | 2002-10-24 |
| CA2326357A1 (en) | 1999-10-07 |
| GB9806739D0 (en) | 1998-05-27 |
| DE69928235T2 (de) | 2006-08-10 |
| EP1066266B1 (de) | 2005-11-09 |
| ES2253881T3 (es) | 2006-06-01 |
| EP1066266A1 (de) | 2001-01-10 |
| DE69928235D1 (de) | 2005-12-15 |
| WO1999050251A3 (en) | 2000-02-03 |
| AU3155199A (en) | 1999-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69928235D1 (de) | Cyclin-abhängige kinase inhibitoren | |
| BR0314001A (pt) | Pirazolopirimidinas como inibidores de cinase dependente de ciclina | |
| MXPA05005199A (es) | Compuestos de pirimidina. | |
| MY137843A (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| MY139336A (en) | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| MY137888A (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| MXPA03010810A (es) | Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos. | |
| MY149044A (en) | Pyrazolopyrimidines - derivatives as cyclin dependent kinase inhibitors | |
| MY134589A (en) | Imidazopyrazines as cyclin dependent kinase inhibitors | |
| WO2002079193A8 (en) | Inhibitors of cyclin dependent kinases as anti-cancer agent | |
| AP9901435A0 (en) | Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors. | |
| PL1758871T3 (pl) | Pirazolopirymidyny | |
| WO1999006540A3 (en) | Inhibitors of cell-cycle progression and uses related thereto | |
| ATE244719T1 (de) | N-7 heterocyclyl-pyrrolo( 2,3-d)pyrimidine und ihre verwendung | |
| NO20006027L (no) | Anvendelse av indigoid-bisindolderivater til fremstilling av et medikament for å hemme cyclinavhengige kinaser | |
| TR200101860T2 (tr) | Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller | |
| BG104938A (bg) | Заместени индолинони, тяхното получаване и тяхното приложение като лекарствени средства | |
| CY1110666T1 (el) | Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων | |
| ATE327242T1 (de) | Neue purine | |
| MY136840A (en) | Pyrazolopyridines as cyclin dependent kinase inhibitors | |
| ECSP066763A (es) | Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes | |
| FI972683A0 (fi) | Kemiallisia yhdisteitä | |
| MXPA02010759A (es) | Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa. | |
| ATE309991T1 (de) | Cyclin abhängige kinase(cdk)4 hemmer und deren verwendung zur behandlung von krebs | |
| BRPI0416777A (pt) | composto de piridinil metanona substituìdos por amino úteis no tratamento de disturbios da quinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |